Manufacturer Supply Enalapril Maleate Intermediate With High Purity
N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine; ECPPA CAS: 82717-96-2
Enalapril Maleate CAS: 76095-16-4
| Chemical Name |
Enalapril Maleate |
| Synonyms |
MK-421; 1-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-L-proline Maleate |
| CAS Number |
76095-16-4 |
| CAT Number |
RF-API60 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C24H32N2O9 |
| Molecular Weight |
492.52 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Crystalline Powder |
| Identification A |
The IR spectrum matches that of RS |
| Identification B |
Major peak in chromatogram obtain in the test solution in the assay accordance with that of reference solution |
| Specific Rotation |
-41.0° ~ -43.5.0° |
| Loss on Drying |
≤1.0% |
| Residue on Ignition |
≤0.20% |
| Heavy Metals |
≤10ppm |
| Related Substances |
|
| Enalaprilat |
≤0.30% |
| Moexipril Related Compound F |
≤0.30% |
| Enalapril Cyclohexyl Analog |
≤0.30% |
| Enalapril Related Compound D |
≤0.30% |
| Any Unspecified Impurity |
≤0.10% |
| Total Impurities |
≤2.0% |
| Residual Solvents |
|
| Ethanol |
≤5000ppm |
| Acetone |
≤5000ppm |
| Dichloromethane |
≤600ppm |
| n-Hexane |
≤290ppm |
| Assay |
98.5%~102.0% (Calculated on the dried basis) |
| Test Standard |
USP Standard; EP Standard; Enterprise Standard |
| Usage |
Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Enalapril Maleate (CAS: 76095-16-4) is an angiotensin converting enzyme inhibitor (ACE), used to treat high blood pressure, diabetes kidney disease, and chronic heart failure. Orally active. An Antihypertensive agent. Enalapril maleate (Vasotec), the active metabolite of enalapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II.